ABT vs NVO: stock comparison and AI forecast
Abbott Laboratories (ABT) and Novo Nordisk A S (NVO) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
ABT Abbott Laboratories
- Price
- $109.40 +25.5% · 6M
- Market Cap
- $190.23B
- P/E Ratio
- 30.6x
- Size
- large-cap
- AI Forecast
NVO Novo Nordisk A S
- Price
- $40.00 -5.3% · 6M
- Market Cap
- $177.76B
- P/E Ratio
- 3.0x
- Size
- large-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- ABT and NVO have similar market capitalizations ($190.23B and $177.76B).
- NVO trades at 3.0 times trailing earnings, ABT at 30.6 times.
- Over the last six months ABT returned +25.5% and NVO -5.3%.
- NVO turns 34.0% of its revenue into net income, against 13.9% for ABT.
- NVO carries 1.80 times debt per unit of equity, against 1.11 times for ABT.
- ABT yields 2.20% in dividends; NVO pays none.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | ABT | NVO |
|---|---|---|
| Market Cap | $190.23B | $177.76B |
| P/E Ratio | 30.64x | 2.97x |
| P/B Ratio | 3.65x | – |
| Dividend Yield | 2.20% | – |
| EPS | $3.57 | $13.48 |
| Book Value/Share | $29.94 | – |
| Revenue/Share | $25.96 | $34.48 |
| FCF/Share | $4.24 | $9.66 |
Profitability & Margins
| Metric | ABT | NVO |
|---|---|---|
| ROE | 12.1% | 176.6% |
| ROA | 5.7% | 63.1% |
| ROIC | 8.4% | 132.4% |
| Gross Margin | 56.3% | 83.4% |
| Operating Margin | 17.1% | 43.0% |
| Net Margin | 13.9% | 34.0% |
| EBT Margin | 18.0% | 42.8% |
| Tax Rate | 22.9% | 20.6% |
Financial Health
| Metric | ABT | NVO |
|---|---|---|
| Current Ratio | 1.39x | 0.80x |
| Quick Ratio | 1.01x | 0.57x |
| D/E Ratio | 1.11x | 1.80x |
| Financial Leverage | 2.12x | 2.80x |
| Interest Coverage | 4.1x | – |
| Working Capital | $7.13B | -$6.79B |
Cash Flow
| Metric | ABT | NVO |
|---|---|---|
| Operating Cash Flow | $9.46B | $64.99B |
| Free Cash Flow | $7.38B | $42.93B |
| Capital Spending | -$2.09B | -$22.06B |
| OCF Growth YoY | 5.7% | 115.7% |
| FCF Growth YoY | 10.8% | 0.0% |
| FCF/Sales | 16.4% | 28.0% |
| CapEx/Sales | 4.6% | 14.4% |
Operational Efficiency
| Metric | ABT | NVO |
|---|---|---|
| Asset Turnover | 0.41x | 1.86x |
| Receivables Turnover | 5.5x | – |
| Inventory Turnover | 2.8x | 3.4x |
| Fixed Assets Turnover | 3.6x | – |
| Days Sales Outstanding | 66 days | – |
| Days Inventory | 129 days | 108 days |
Income Statement
| Metric | ABT | NVO |
|---|---|---|
| Total Revenue | $45.13B | $153.22B |
| Operating Income | $7.71B | $65.83B |
| Net Income | $6.28B | $52.04B |
| R&D Expense | $2.99B | $23.79B |
| SG&A Expense | $13.01B | – |
| Cost of Goods Sold | $19.74B | $25.45B |
Dividend & Shareholder Information
| Metric | ABT | NVO |
|---|---|---|
| Dividends Per Share | $2.41 | – |
| Payout Ratio | 67.5% | – |
| Shares Outstanding | 1739M | 4444M |
| Net Income Growth | -53.5% | 104.6% |
| EPS Growth | -53.6% | 24.9% |
ABT vs NVO: stock comparison and AI forecast
Which is bigger, ABT or NVO?
ABT and NVO have similar market capitalizations ($190.23B and $177.76B).
Which is cheaper on earnings, ABT or NVO?
NVO trades at 3.0 times trailing earnings, ABT at 30.6 times.
Which stock performed better over the last six months, ABT or NVO?
Over the last six months ABT returned +25.5% and NVO -5.3%.
Which one does Intratio's AI model rank higher, ABT or NVO?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.